Your browser version may not work well with NCBI's Web applications. More information here...
1: Mini Rev Med Chem. 2002 Feb;2(1):11-25.Click here to read Links

Cholinergic drugs in pharmacotherapy of Alzheimer's disease.

Camps P, Muñoz-Torrero D.

Laboratori de Química Farmacèutica, Facultat de Farmàcia, Universitat de Barcelona, Spain. camps@farmacia.far.ub.es

The cholinergic hypothesis of Alzheimer's disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimer's disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M(1) muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.

PMID: 12369954 [PubMed - indexed for MEDLINE]